AUPH Key Statistics, Chart & Performance
The current stock price of AUPH is 14.85 USD. In the past month the price decreased by -5.95%. In the past year, price increased by 85.39%.
AUPH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AUPH. When comparing the yearly performance of all stocks, AUPH is one of the better performing stocks in the market, outperforming 93.4% of all stocks.
AUPH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AUPH. AUPH has an excellent financial health rating, but there are some minor concerns on its profitability.
AUPH Financial Highlights
Over the last trailing twelve months AUPH reported a non-GAAP Earnings per Share(EPS) of 0.56. The EPS increased by 609.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.28% | ||
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| Debt/Equity | 0.15 |
AUPH Forecast & Estimates
13 analysts have analysed AUPH and the average price target is 17.05 USD. This implies a price increase of 14.81% is expected in the next year compared to the current price of 14.85.
For the next year, analysts expect an EPS growth of 772.67% and a revenue growth 19.09% for AUPH
AUPH Ownership
AUPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About AUPH
Company Profile
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company is headquartered in Edmonton, Alberta. The company went IPO on 2001-07-16. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Company Info
AURINIA PHARMACEUTICALS INC
#140, 14315 - 118 Avenue
Edmonton ALBERTA V8Z 7X8 CA
CEO: Peter Greenleaf
Employees: 300
Phone: 12507442487
AURINIA PHARMACEUTICALS INC / AUPH FAQ
Can you describe the business of AURINIA PHARMACEUTICALS INC?
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company is headquartered in Edmonton, Alberta. The company went IPO on 2001-07-16. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
What is the stock price of AURINIA PHARMACEUTICALS INC today?
The current stock price of AUPH is 14.85 USD. The price decreased by -0.13% in the last trading session.
What is the dividend status of AURINIA PHARMACEUTICALS INC?
AUPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of AUPH stock?
AUPH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for AURINIA PHARMACEUTICALS INC?
AURINIA PHARMACEUTICALS INC (AUPH) operates in the Health Care sector and the Biotechnology industry.
Should I buy AUPH stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AUPH.
What is the expected growth for AUPH stock?
The Revenue of AURINIA PHARMACEUTICALS INC (AUPH) is expected to grow by 19.09% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.